Compare Davita Inc (DVA) vs The Coca-Cola Co K (KO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs The Coca-Cola Co K — how do they compare? Davita Inc trades at $178.35 (market cap $11.72B), while The Coca-Cola Co K trades at $86.57 (market cap $373.76B). The key difference: The Coca-Cola Co K is far larger — about 31.9× Davita Inc's market cap, and The Coca-Cola Co K pays a 2.44% dividend while Davita Inc pays none. Which is the better fit depends on your goals.
| DVA | KO | |
|---|---|---|
Market Cap | $11.72B | $373.76B |
Sector | Health | Consumer Staples |
52-Week High | $240.96 | $89.08 |
52-Week Low | $103.87 | $65.67 |
Enterprise Value | $24.44B | $400.93B |
Volume | — | 14,630,257 |
Dividend Yield | — | 2.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $183.77, up 1.72% today, with a mixed technical picture showing bearish moving averages but bullish oscillators. The company reported strong Q2 2026 earnings of $4.02 per share, beating estimates, driven by volume growth. Revenue reached $13.64 billion in 2025, with a net income margin of 6.05%. Analyst consensus is a Buy with a $232.25 price target, though technical signals are bearish overall.
The outlook for DVA is cautiously optimistic, supported by earnings beats and volume growth, but risks include reimbursement pressure and high debt levels. The stock offers potential upside to the consensus target, yet investors face headwinds from margin compression and technical bearishness.
Coca-Cola (KO) trades at $86.48, down 0.65% on the day, with a bullish technical signal supported by moving averages and oversold RSI levels. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $0.97 exceeding the $0.92 estimate, and maintains robust profitability with a 28.56% net margin. Recent news highlights institutional buying and stable demand trends, while dividends continue with a $0.53 payout.
The outlook is positive with a consensus price target of $95.83 implying 11% upside, driven by earnings momentum and dividend reliability. Risks include regional demand volatility and high debt levels, but analyst sentiment is bullish with 60% buy ratings. The stock presents a steady growth opportunity with defensive income characteristics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About The Coca-Cola Co K
The Coca-Cola Company manufactures, markets, and distributes soft drink concentrates and syrups. The Company also distributes and markets juice and juice-drink products. Coca-Cola distributes its products to retailers and wholesalers in the United States and internationally.
Read more on KO →
